Non-Alcoholic Steatohepatitis Treatment Market, by Drug, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Non-alcoholic steatohepatitis (NASH) is the advanced form of non alcoholic fatty liver disease (NAFLD), a chronic disease marked by excessive fat accumulation in the liver. Nonalcoholic steatohepatitis (NASH) is a form of nonalcoholic fatty liver disease (NAFLD) in which a person have hepatitis and inflammation of the liver, which can cause liver damage. NASH can lead to complications, such as cirrhosis and liver cancer. Patients with NASH have high chance of mortality due to liver-related causes such as liver failure. Lifestyle modification, including change in diet and exercise, is the basic therapy recommended for nonalcoholic fatty liver disease. However, in some cases lifestyle modification is difficult to achieve and to sustain, and therefore requires other treatments including medicine. Currently available drugs for the treatment of NAFLD were historically being given for other indications. For instance, Orlistat, a gut lipase inhibitor, is indicated for decrease in the dietary fats absorption. According to the National Center for Biotechnology Information (NCBI) 2017 study, Orlistat has been approved for treatment of obesity and is available over the counter in the U.S. for weight loss. Orlistat-mediated weight loss is related with reduction in hepatic steatosis.

Market Dynamics

Obesity, high blood pressure and cholesterol level, type 2 diabetes and metabolic syndrome are the major causes of the nonalcoholic steatohepatitis onset. Increasing prevalence of these conditions worldwide is expected to drive the global nonalcoholic steatohepatitis treatment market growth during the forecast period. According to the International Diabetes Federation 2017 data, approximately 425 million people were suffering from diabetes in the world and 82 million cases were in the South East Asia region which is expected to reach 151 million by 2045. Moreover, in December 2021, according to the National Center for Biotechnology Information, in the U.S., the frequency of insulin resistance was observed to be 3% in the general population; a several-fold increase occurs in individuals with glucose intolerance. Worldwide, the prevalence of insulin resistance ranges from 15.5 to 46.5%, among adults. The total number of people with diabetes would rise from ∼11 million in 2000 to almost 20 million in 2025. By 2050, this is projected at >29 million people - a 165% increase over the 2000 level. It is to be noted that these projections imply a steady increase in the overall prevalence of diabetes, from 3.99% in 2000 to 7.21% in 2050.

However, diagnosis of the nonalcoholic steatohepatitis can be difficult to capture in an early stage and can take years before patients show any sort of symptoms which is a major factor hampering the nonalcoholic steatohepatitis treatment market.

Key features of the study:

• This report provides an in-depth analysis of the global nonalcoholic steatohepatitis treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global nonalcoholic steatohepatitis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global nonalcoholic steatohepatitis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nonalcoholic steatohepatitis treatment market

Detailed Segmentation:

Global Nonalcoholic Steatohepatitis Treatment Market, By Drug:

• Cenicriviroc
• Elafibranor
• Ocaliva (Obeticholic Acid)
• Selonsertib

Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Nonalcoholic Steatohepatitis Treatment Market, By Region:

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC
• Israel
• Rest of Middle East
• Africa
• South Africa
• Central Africa
• North Africa

Company Profiles:

• AstraZeneca Plc.
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Conatus Pharmaceuticals
• Enzo Biochem, Inc.
• GENFIT SA
• Galmed Pharmaceuticals Ltd.
• Gilead Science
• Immuron Ltd.
• Intercepts Pharmaceuticals
• Novo Nordisk
• Raptor Pharmaceutical Corporation
• Tobira Therapeutics, Inc.